Analysts Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $20.00

Altimmune, Inc. (NASDAQ:ALT) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $19.71.

A number of analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Thursday, November 14th. UBS Group began coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company. Finally, Stifel Nicolaus began coverage on Altimmune in a research report on Wednesday. They set a “buy” rating and a $18.00 price objective on the stock.

Altimmune Stock Down 7.8 %

Altimmune stock opened at $6.87 on Tuesday. The business has a 50-day simple moving average of $8.10 and a 200 day simple moving average of $7.20. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84. The stock has a market cap of $488.63 million, a price-to-earnings ratio of -4.43 and a beta of 0.22.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million for the quarter. During the same quarter last year, the company posted ($0.39) earnings per share. On average, research analysts anticipate that Altimmune will post -1.36 earnings per share for the current year.

Hedge Funds Weigh In On Altimmune

A number of large investors have recently bought and sold shares of ALT. B. Riley Wealth Advisors Inc. grew its stake in shares of Altimmune by 12.9% in the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock worth $144,000 after purchasing an additional 2,687 shares during the last quarter. Creative Planning grew its position in shares of Altimmune by 20.5% in the 3rd quarter. Creative Planning now owns 18,411 shares of the company’s stock worth $113,000 after buying an additional 3,132 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after buying an additional 4,772 shares during the period. Larson Financial Group LLC bought a new position in shares of Altimmune during the third quarter valued at approximately $31,000. Finally, Arizona State Retirement System lifted its stake in Altimmune by 34.4% in the second quarter. Arizona State Retirement System now owns 19,847 shares of the company’s stock worth $132,000 after acquiring an additional 5,081 shares during the period. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.